151135-82-9

Usage

Uses

Used in Pharmaceutical Industry:
Kanzonol C is used as an anti-cancer agent for its ability to inhibit the growth of cancer cells. It targets various signaling pathways and mechanisms involved in cancer progression, making it a potential therapeutic option for cancer treatment.
Kanzonol C is also used as an anti-inflammatory agent for its capacity to reduce inflammation in various disease conditions. Its anti-inflammatory properties can be beneficial in managing inflammatory disorders and related health issues.
Used in Cosmetics Industry:
Kanzonol C is used as an antioxidant ingredient in cosmetics for its ability to protect the skin from oxidative stress and environmental damage. Its antioxidant properties can help maintain skin health, prevent premature aging, and support overall skin wellness.
Used in Nutraceutical Industry:
Kanzonol C is used as a nutraceutical ingredient for its potential health benefits, including its antioxidant and anti-inflammatory properties. It can be incorporated into dietary supplements and functional foods to support overall health and well-being.

Upstream product

• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 89024-12-4 (E)-1-(2-hydroxy-4-(methoxymethoxy)-3-(3-methylbut-2-en-1-yl)phenyl)-3-(4-(methoxymethoxy)-3-(3-methylbut-2-en-1-yl)phenyl)prop-2-en-1-one 
• 74021-58-2 4-methoxymethoxy-3-(3-methyl-but-2-enyl)-benzaldehyde 
• 54730-26-6 4-methoxymethoxy-3-(3,3-dimethylallyl)-2-hydroxyacetophenone 
• 1314539-20-2 2'-prenyloxy-4'-methoxymethoxyacetophenone 
• 65490-08-6 2-hydroxy-4-(methoxymethoxy)acetophenone 
• 870-63-3 prenyl bromide 
• 115-18-4 2-methyl-3-buten-2-ol 
• 54730-30-2 4-hydroxy-3-C-prenylbenzaldehyde 
• 123-08-0 4-hydroxy-benzaldehyde 
• 19825-40-2 2,4-Dihydroxy-3-C-prenylacetophenone 

Relevant academic research and scientific papers

Synthesis and antibacterial activity of four natural chalcones and their derivatives

Four natural chalcones bearing hydroxyisoprenyl or prenyl groups, named Paratocarpin E (2), Xanthoangelol D (3), Angusticornin A (4) and Kanzonol C (5), were prepared by employing the Claisen-Schmidt condensation as the key step. In an attempt to investigate the effect of the hydroxyisoprenyl group on biological activity, two of their derivatives were also prepared for antibacterial activity research. The synthesized compounds were investigated for their expected antibacterial activities against Gram positive bacteria (Bacillus subtilis, Staphylococcus aureus) as well as Gram negative bacteria (Escherichia coli, Pseudomonas aeruginosa). Paratocarpin E (2) was found to be the most potent against two Gram positive bacteria while the majority of the remaining compounds showed promising activity as well. However, all of the compounds were inactive against both Gram-negative bacteria.

Synthetic method and application of natural product Kanzonol C and derivatives thereof

The invention discloses a synthetic method and application of a natural product Kanzonol C and derivatives thereof. The structural formula (I) and (II) are shown in the specification: compared with anatural product Kanzonol C, the obtained novel isopenten

Synthetic methods for prenylated chalcones and pyranochalcones

The inventors of the present invention invented a simple and effective way to synthesize compounds 1-9 of natural prenylated chalcones and pyrano chalcones by using Claisen-Schmidt condensation as a main step. In addition, an anti-inflammatory effect of synthetic compounds was evaluated in RAW 264.7 macrophages which were stimulated with a lipopolysaccharide. As a result, chalcone compounds having prenyl groups in a ring A (an acetophenone part) show weak inhibition or no inhibition on the generation of nitrogen oxide while chalcones (5, 6, 8, and 9) having no prenyl groups in the ring A show normal or good activity, and have no cytotoxicity.COPYRIGHT KIPO 2017

Synthesis and pharmacological properties of naturally occurring prenylated and pyranochalcones as potent anti-inflammatory agents

An efficient approach has been developed for the synthesis of naturally occurring prenylated chalcones viz. kanzonol C (1), stipulin (2), crotaorixin (3), medicagenin (4), licoagrochalcone A (5) and abyssinone D (6) along with the pyranochalcones paratocarpin C (7), anthyllisone (8) and 3-O-methylabyssinone A (9). The key step of the synthesis is a Claisen-Schmidt condensation. Subsequently, their anti-inflammatory effects were investigated in lipopolysaccharides (LPSs)-induced RAW-264.7 macrophages. Of the synthesized chalcones, compounds 5 (IC50 = 10.41 μmol/L), 6 (IC50 = 9.65 μmol/L) and 8 (IC50 = 15.34 μmol/L) show remarkable activity with no cytotoxicity. Compound 9 (IC50 = 4.5 μmol/L) exhibits maximum (83.6%) nitric oxide (NO) inhibition, but shows slight cytotoxicity. The results reveal that the chalcones bearing the prenyl group at 3- and/or 5-position on ring A (acetophenone moiety), i.e., 1-4 and 7 show weak, or no inhibition activity, whereas chalcones having the prenyl group only on ring B (aldehyde part), i.e., 5, 6 and 8 show significant activity on the production of inflammatory mediated NO with no cytotoxicity.